Summary Human epithelial ovarian tumours were successfully established as xenografts in nude mice in 54% of cases. An evaluation of the biological characteristics of tumours propagated in nude mice was carried out and the functions investigated included morphology, growth kinetics, cellular DNA content, cell surface antigen expression and sensitivity to chemotherapy. To allow a more detailed study of the influence of ploidy on biological behaviour, xenografted tumour with varying degrees of aneuploidy and tumours with a common ancestry but different ploidies were also established. Although this is a highly selective model system favouring the growth of biologically aggressive tumours the xenografts, in general, reflect many of the characteristics of the tumours from which they were derived and are likely to provide a useful model for investigating the biology of ovarian cancer.
The development of the congenitally athymic mouse mutant has provided a host that supports growth of human malignant tumours and offers unique possibilities to study the biology of human tumours in vivo. Of paramount importance in assessing the value of the xenograft model has been the evaluation of biological characteristics of tumours propagated in nude mice compared to those of the parent (donor) tumour. The general consensus reached in a number of studies encompassing a variety of tumour types is that human tumour xenografts largely reflect the features of the donor tumour with the exception of proliferation kinetics and metastatic properties (for reviews see Shimosata et al., 1982; Povlsen et al., 1982) . However, there have been few detailed studies on the utility of ovarian tumour xenografts (Davy et al., 1977; Kullander et al., 1978; Teufel et al., 1981; Van Haaften Day et al., 1983) . The aims of this study were two fold, firstly to investigate biological characteristics of ovarian tumour xenografts compared with those of the original tumour from which they were established, and secondly to establish a model system of xenografted tumours with different ploidies. Results of clinical flow cytometric studies have indicated that cellular DNA content is of prognostic importance in ovarian epithelial tumours (Friedlander et al., 1984a, b) as well as in a number of other tumour types (for review see Friedlander et al., 1984c) yet the fundamental reasons for this remain obscure. Establishment of diploid ovarian tumours together with tumours with varying degrees of aneuploidy in nude mice would allow more detailed study of the possible relationship between tumour ploidy and biological behaviour.
Materials and methods
Ovarian tumour xenografts Establishment and maintenance ofxenografts Female BALB/c nude mice were obtained from the Australian Atomic Energy Commission, Lucas Heights, NSW, and housed in laminar flow racks and provided with sterilised food and drinking water ad libitum. Sterilised gloves, clean gowns, face masks and caps were used when handling the animals.
Tumour tissue was obtained directly from the operating theatre under sterile conditions, placed in RPMI 1640 medium containing 10% foetal calf serum and dissected into fragments measuring 3-5 mm in diameter. A sample was set aside for flow cytometry and histology. Xenografts were established in 6 week old mice by inoculating these fragments s.c., using fine forceps, through a small incision in the scapular region of the mouse. The incision was sutured with fine silk, a procedure which improved the take rate by ensuring fragments remained in place. Bilateral implantation was performed in all instances under ether anaesthesia. Depending on the size of tumour sample obtained 3-5 mice were used in the attempt to establish xenografts.
When establishing xenografts from ascites or from in vitro cell lines, -5 x 107 cells were injected s.c. in 0.1-0.2ml of medium. The effusions were collected under sterile conditions, centrifuged at 200g for 10min in 50ml propylene centrifuge tubes (Corning Glass Company, Corning, NY) and the pellet resuspended in phosphate buffered saline (PBS) and washed twice prior to inoculation.
A tumour "take" was defined as a tumour which grew progressively after implantation and could be serially passaged. In the event of no growth occurring 8 months-1 year after implantation of the original tumour from the patient, the mice were sacrificed and this was defined as negative take.
When the tumours reached a size of 10-15mm in diameter they were serially passaged by s.c. implantation of explants of xenografted tissue as described above. At this time samples of tissue were taken for flow cytometry and also fixed in combined formalin, acetic acid and alcohol (FAA) for subsequent histological examination. Autopsies were performed on most of these mice and specimens fixed in FAA for histological examination if there was macroscopic evidence of metastasis.
Growth characteristics Tumours were measured weekly, when they achieved a size of 3-5mm in diameter, using graduated calipers. Growth curves were expressed as tumour size versus time, where the area (mm2) was calculated by using the formula for an ellipse, dl d2 7 +--x 2 2 with dl and d2 representing the maximum diameters of the tumour measured at right angles (Teufel et al., 1981) .
Median tumour size was plotted against time and the doubling time (TD) found by interpolation on a semi-logarithmic plot (Steel et al., 1983 (Taylor, 1980; Friedlander et al., 1983) , on all primary tumour specimens, after most routine passages of "stock" tumours and on tumours implanted for chemosensitivity testing. (Miller et al., 1981) . Single agent chemotherapy was given by intraperitoneal injection, the therapeutic dosage being determined in a series of toxicity experiments by treating groups of 5 mice with varying dose levels. The maximum tolerated dose (MTD) was used and defined as the drug dose that caused <20% decrease in body weight and did not kill any mice.
The final doses used in chemosensitivity testing were as follows: Cisplatinum 5 mg kg l i.p. weekly x 4. Melphalan 5 mg kg i.p. weekly x 4. Drugs were freshly made up for each experiment. Control animals were treated with normal saline (in the case of cisplatinum treatment) or with melphalan diluent (in the case of melphalan therapy) in an equivalent volume, and control and test tumour growth curves were compared. In the majority of experiments there were 5 animals in the treated and control groups. Tumours were measured weekly using calipers, as described earlier.
Histology
Specimens for histological examination were taken from the tumours destined for implantation and also from the resulting xenograft. Tissues were routinely fixed in FAA both for cytomorphology and immunocytochemical staining.
Immunocytochemical staining was performed using the immunoperoxidase technique described. The antigens investigated included; CA, a putative cancer specific antigen (Ashall et al., 1982) ; CA125, a Mullerian differentiation antigen (Kabawat et al., 1983) ; EMA, an epithelial membrane antigen (GG, JN, JV2) . DI= DNA index, this represents the ratio of the DNA content of tumour G1 cells to the diploid G1 peak. of these lines in subsequent passages was 81 % with the lowest take rate of 50% occurring in the diploid line (Table II) . The cytomorphology of the original tumours were usually maintained following xenotransplantation although there were often minor differences in architecture presumably due to a different stromal reaction. There was no evidence of increased differentiation occurring in any of the tumours, the majority of the original tumours were poorly differentiated (Grade III) and remained so in subsequent passages. Three tumours (FF, JV, DO) were moderately well differentiated when initially implanted and have maintained their morphology (Figure la, b ), but they have been through only few passages to date. In contrast those tumours which had been initially established in cell culture and passaged up to 14 times before being implanted became progressively less differentiated following xenografting (Figure ic) Table III and disclose no appreciable differences in the expression of these antigens between the xenografted and donor tumours (Figure 2) . The patterns and distribution of staining of EMA, CA1 and OC12%were similar in the xenografted tumour tissue although, there was a greater degree of cytoplasmic staining present, Cisplatinum and chlorambucil were then given for 1 year and she remains in complete remission (documented surgically) 2 years after completing treatment. In the xenografted line there was a complete regression with cisplatinum (6/8 tumours) and melphalan (10/10 tumours) with no evidence of regrowth occurring during the period of observation of 10 weeks. This sensitivity to melphalan is of interest as it is quite possible that the recurrent tumour could have developed from a resistant subpopulation of the original tumour and therefore be resistant to alkylating agents.
Patient JC was treated with cisplatinum and chlorambucil and after an initial brief partial response rapidly developed progressive drug resistant disease. A xenograft was established from ascitic fluid which was tapped for symptomatic relief when the patient was pre-terminal. The tumour established in the mice had a paradoxical response as growth delay occurred with both cisplatinum (2.5) and melphalan (1.4). Xenograft morphology and ploidy were similar to those of the original tumour.
Patients GGI and JN had recurrent carcinoma Table V demonstrate that the DNA Index (DI) and S phase fraction remain essentially unchanged following serial passage. Mean variation of the DI before and after passage in nude mice was 5% (range 0-10%), a result consistent with staining and instrumental variation (Taylor & Milthorpe, 1980 following implantation before it became measurable (-3 mm in diameter). The transplant take rate is only 50% and spontaneous regressions of the tumour have been noted occasionally (< 5% of tumours). The influence of quantitative differences of tumour cell DNA content on biological behaviour, was investigated by attempting to establish xenografted tumours with common ancestry yet different degrees of aneuploidy ( Figure 5 ). JVI is a serious tumour with a DI of 0.86 that was established directly in the mouse, while JV2 was inoculated in nude mice from cells obtained after the original tumour had been grown in tissue culture for 14 passages. The latter cells exhibited a doubling of DNA content in the third passage in vitro and have remained stable thereafter (DI= 1.5). JV2 had a modal number of 64 chromosomes prior to implantation. The JV2 xenograft line is less well differentiated than JVl but is still serous in type and expresses the same surface antigens as JV1 (see Table III ). The two lines have quite different responses to chemotherapy, as described earlier.
Another model exists in the GG xenograft line where GGI is an aneuploid (DI= 1.7) clear cell carcinoma initially established in nude mice after being propagated in tissue culture and GG2 is a variant (DI=2.8) that arose spontaneously following the implantation of GGl in a castrated male mouse. These lines have a human karyotype and the ploidy has remained stable over 10 subsequent passages. Both lines are EMA and CA1 positive, OC125 negative and histologically poorly differentiated. GG2 differs from GGI in being relatively sensitive to cisplatinum but both lines are resistant to melphalan.
Discussion
Attempts have been made to establish a series of epithelial ovarian tumours in congenitally athymic mice to investigate their biological characteristics and to determine whether they provide a suitable model of human ovarian cancer. The extent to which a human tumour xenograft reflects and maintains the properties of the original source tumour is an essential feature favouring the use of xenografts over that of syngeneic animal tumours as models of human cancer. In this study, xenografted tumours have been compared with the original tumour with respect to their morphological features, cell surface markers, cellular DNA content, proliferative fraction and where possible, therapeutic responsiveness. The results indicate good correlation in such characteristics as morphology, surface antigen expression and cellular DNA content between parent and xenografted tumour. These findings are in keeping with those reported in a number of other tumour types Reeves et al., 1978; Raghavan et al., 1980 Raghavan et al., , 1981 Giovanella et al., 1983) . The majority of successfully implanted tumours were poorly differentiated Channel number Figure 5 DNA histograms of ovarian carcinoma xenografts demonstrating the different ploidies obtained from the same tumour. JV1, established directly from the patient and JV2 established as a xenograft after the tumour was propagated in tissue culture for 14 passages. GG1, established as a xenograft after 10 passages in culture and GG2 exhibits the change in ploidy that occurred spontaneously when GG1 was growing in a castrated male mouse. initially and have remained so. Three moderately differentiated (Grade 2) tumours have maintained their degree of differentiation following xenografting but they have been through relatively few passages and it remains to be seen whether this will continue over longer periods of time.
The xenografted tumour functions that remain stable during serial transplantation include the continued production of melanin in melanomas (Povlsen, 1976) , CEA in colorectal carcinomas (Houghton & Taylor, 1978) , ,BHCG in choriocarcinomas (Kim et al., 1978) and AFP in teratomas (Raghavan et al., 1981) . Relatively little has been previously published on the expression of cell surface antigens and tumour marker production in epithelial ovarian tumour xenografts and the current series demonstrates the consistency in the expression of two differentiation antigens (EMA and CA125) and a putative human cancer specific antigen (CA antigen) in xenografted tumours and their original source tumours. There is some controversy regarding the incidence of CEA and AFP positivity in ovarian epithelial ovarian tumours (for review see Raghavan et al., 1984) . The absence of CEA in all xenografts as well as failure to demonstrate AFP in all but one tumour (in which only a few isolated cells stained), correlated with the findings in the original tumour and is in keeping with the majority of reports of tumour marker production in ovarian epithelial neoplasms.
As we have reported previously, the cellular DNA content remained stable during serial passage of ovarian tumour xenografts and in all but one, case closely resembled that of the original tumour (Friedlander et al., 1984d) . This confirms the findings of DNA content and karyotypic stability noted in other xenografted tumour types (Povlsen & Jacobson, 1975 , Povlsen et al., 1982 Linderberger, 1981; Tilgen et al., 1983 ) and contrasts with observations in tissue culture that changes in DNA cont- ent and modal chromosomal number are common (Van Haaften Day et al., 1983; Bigner et al., 1984) . The reasons for this variability in ploidy are not clear, but the finding that similar changes take place when "normal" mouse keratinocytes are grown in tissue culture, (particularly in the presence of low calcium concentrations in the medium) suggests that changes in cell physiology following the adaption to growth in culture are reflected in, or even caused by genetic alterations (Fusenig et al., 1982) . This genetic instability is a limitation of the in vitro model system. The apparent difference in the biological behaviour of diploid and aneuploid tumours noted in the clinical setting therefore require a suitable in vivo model to facilitate further study. The S phase fraction has been previously reported to vary within different regions of epithelial ovarian tumours (Friedlander et al., 1984d) . This variability was also evident in xenografted tumours, the S phase fraction being higher in well vascularised areas compared with poorly vascularised areas. These findings are consistent with those of Selby et al. (1979) who found that labelling indices were similar in donor and xenograft tumours, but cells at the periphery had a higher labelling index than those in the central region.
It has been suggested that the most precise and relevant way of validating the xenograft system for therapeutic purpose is to directly compare xenograft response with the clinical response of the donor patient (Steel et al., 1983) . However apart from the fact that the pharmacokinetics of anticancer drugs in tumour-bearing mice are poorly understood, there are also difficulties relating to the scheduling of treatment and the method of quantitating tumour response. Tumour growth delay can be influenced by such factors as the dosage and scheduling of drugs used, the site of the tumour and the immune response (Steel & Peckham, 1980; Warenius et al., 1980) . These problems are reflected in the results of therapeutic testing where at times a discordant therapeutic response between patient and xenografted tumour was seen. It was possible to compare response to chemotherapy of 7 xenografted tumours with that of the patient from which the xenografts were derived. In 4 instances there was a good correlation between responses observed while in 3 cases the results of treatment were somewhat different. The latter included; one patient who had no evidence of tumour following treatment with cisplatinum and cyclophosphamide yet the xenograft exhibited only minimal growth delay with cisplatinum and melphalan; one patient with a tumour clinically resistant to cisplatinum and chlorambucil, the growth of which in nude mice was temporarily inhibited during therapy but regrew rapidly after treatment; and one patient whose tumour was clinically resistant to cisplatinum and chlorambucil but where the xenograft responded completely to cisplatinum. There were some differences however, in the treatment of patients and xenografts as only single agents at the maximum tolerated dose were used in the xenograft system while patients usually received combination chemotherapy. Furthermore, the bulk of tumour present in patients differed from that in xenografts, a factor which may influence response to treatment.
Two of the three ovarian tumour lines propagated in tissue culture prior to being established as xenografts responded to therapy differently to that seen in the patient. It is conceivable that the genotypic and phenotypic changes which occur during cell culture could account for this difference. It has been previously claimed that xenografts may be useful in the selection of appropriate chemotherapy of individual patients (Giovanella et al., 1983) . However, the relatively low take rates, the long delay between establishing and subsequently testing xenografts, and the not uncommon paradoxical results seen with treatment would appear to preclude xenografted tumours having a predictive role in the choice of treatment for individual patients. In the therapeutic setting, the place of ovarian xenografts may be rather the primary screening of new drugs and testing novel experimental approaches to treatment such as hormonal therapy or the Mullerian Inhibitory Substance. The major differences between xenografted and human ovarian tumours include the very low incidence of metastases in nude mice, and a tumour doubling time (mean= 14 days) that is far more rapid than already seen clinically (Steel & Peckham, 1980) . The reasons for these differences are not known but it has been postulated that tumours that grow in mice are either selected for rapid growth or increase their growth rate in the new environment. Although the S phase and labelling indices are slightly higher in the xenografted tumour than in the original tumour, the differences are not large enough to explain the differences in doubling time, and a decreased cell loss factor may be important contributing factor (Rofstadt et al., 1982) . In addition, the xenograft model is a highly selective system which favours growth of tumours that in most instances are aggressive, aneuploid, poorly differentiated and disseminated at the time of diagnosis. These selection pressures make this model system unsuitable for investigating the biology of the whole spectrum of ovarian epithelial tumours. Only one diploid line from a patient with a Stage Ia ovarian cancer was established. While it is possible that this line may be a useful model for further study the fact that it grows as a xenograft may indicate that it is biologically different to the group of diploid ovarian tumours previously reported to have a relatively good prognosis. Further attempts to establish "biologically indolent" tumours are warranted as there are reports in other tumour types of benign and low grade tumours being successfully implanted (McManus et al., 1978) .
In conclusion, the findings of this study suggest that ovarian tumour xenografts, in general, reflect the biological characteristics of the tumours from which they are derived. Notwithstanding the number of limitations, tumour xenografts will be a useful model for exploring some of the biological properties of human ovarian cancer. Possible directions for future studies using xenografts include investigation into the degree of genetic instability, mutation rate, oncogene expression and acquisition of drug resistance in xenograft lines established from tumours that vary in their clinical behaviour.
